<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">340799</article-id><article-id pub-id-type="doi">10.26442/20795696.2023.4.202366</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>REVIEWS AND CASE REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОБЗОРЫ И КЛИНИЧЕСКИЕ СЛУЧАИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Menopause and premature ovarian insufficiency in rheumatic diseases: A review</article-title><trans-title-group xml:lang="ru"><trans-title>Менопауза и преждевременная недостаточность яичников при ревматических заболеваниях</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5290-156X</contrib-id><contrib-id contrib-id-type="spin">7839-3145</contrib-id><name-alternatives><name xml:lang="en"><surname>Panevin</surname><given-names>Taras S.</given-names></name><name xml:lang="ru"><surname>Паневин</surname><given-names>Тарас Сергеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, науч. сотр. отд. воспалительных заболеваний суставов, врач-эндокринолог ФГБНУ «НИИ ревматологии им. В.А. Насоновой», ассистент каф. факультетской и поликлинической терапии с курсом эндокринологии ФГБОУ ВО ДВГМУ</p></bio><email>tarasel@list.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6354-0475</contrib-id><name-alternatives><name xml:lang="en"><surname>Ledina</surname><given-names>Antonina V.</given-names></name><name xml:lang="ru"><surname>Ледина</surname><given-names>Антонина Виталиевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Russian Association of Genital Infections and Neoplasia</p></bio><bio xml:lang="ru"><p>доктор медицины наук, доцент каф. акушерства и гинекологии ФГАОУ ВО РУДН, вице-президент Общероссийской общественной организации «РАГИН», врач Клинического госпиталя Лапино «Мать и дитя»</p></bio><email>antoninaledina@yandex.ru</email><xref ref-type="aff" rid="aff3"/><xref ref-type="aff" rid="aff4"/><xref ref-type="aff" rid="aff5"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4579-2836</contrib-id><name-alternatives><name xml:lang="en"><surname>Zotkin</surname><given-names>Evgeniy G.</given-names></name><name xml:lang="ru"><surname>Зоткин</surname><given-names>Евгений Германович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Nasonova Research Institute of Rheumatology</p></bio><bio xml:lang="ru"><p>доктор медицины наук, 1-й зам. дир. ФГБНУ «НИИ ревматологии им. В.А. Насоновой»</p></bio><email>ezotkin@mail.ru</email><xref ref-type="aff" rid="aff6"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Far-East State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Дальневосточный государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">People’s Friendship University of Russia (RUDN University)</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»</institution></aff></aff-alternatives><aff-alternatives id="aff4"><aff><institution xml:lang="en">Russian Association of Genital Infections and Neoplasia</institution></aff><aff><institution xml:lang="ru">Общероссийская общественная организация «Российская ассоциация по генитальным инфекциям и неоплазии»</institution></aff></aff-alternatives><aff-alternatives id="aff5"><aff><institution xml:lang="en">Lapino Clinical Hospital “Mother and Child”</institution></aff><aff><institution xml:lang="ru">Клинический госпиталь Лапино «Мать и дитя»</institution></aff></aff-alternatives><aff-alternatives id="aff6"><aff><institution xml:lang="en">Nasonova Research Institute of Rheumatology</institution></aff><aff><institution xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2023-11-16" publication-format="electronic"><day>16</day><month>11</month><year>2023</year></pub-date><pub-date date-type="pub" iso-8601-date="2023-12-20" publication-format="electronic"><day>20</day><month>12</month><year>2023</year></pub-date><volume>25</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>428</fpage><lpage>434</lpage><history><date date-type="received" iso-8601-date="2023-04-25"><day>25</day><month>04</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-09-15"><day>15</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2023, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2023, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/340799">https://gynecology.orscience.ru/2079-5831/article/view/340799</self-uri><abstract xml:lang="en"><p>Premature ovarian insufficiency (POI) is a clinical syndrome defined as loss of ovarian function before the age of 40 years. Among the causes of POI are genetic, metabolic disorders, as well as infectious or iatrogenic factors, but in some cases the exact cause cannot be established. Given the possible association of ovarian failure with autoimmune disorders, as well as the detection of antibodies to normal ovarian tissue in the serum of patients with POI, it is assumed that an autoimmune mechanism is a significant cause of the syndrome. Taking into account the relationship between POI and autoimmune diseases, it seems relevant to address the issues of mutual influence of the ovarian function of women with POI and rheumatic diseases (in particular, systemic lupus erythematosus, rheumatoid arthritis and systemic scleroderma), which is presented in this review. Hormone replacement therapy may be recommended for women with POI to improve their quality of life.</p> <p>Keywords: premature ovarian insufficiency, menopause, anti-ovarian antibodies, systemic lupus erythematosus, rheumatoid arthritis, systemic scleroderma, rheumatic diseases, hormone replacement therapy.</p></abstract><trans-abstract xml:lang="ru"><p>Преждевременная недостаточность яичников (ПНЯ) – это клинический синдром, определяемый как потеря функции яичников в возрасте до 40 лет. Среди причин ПНЯ – генетические, обменные нарушения, а также инфекционный или ятрогенный факторы, однако в ряде случаев точную причину установить не удается. Учитывая возможную ассоциацию недостаточности яичников с аутоиммунными нарушениями, а также обнаружение антител к нормальной ткани яичников в сыворотке крови пациенток с ПНЯ, предполагается, что аутоиммунный механизм является значимой причиной синдрома. Принимая во внимание взаимосвязь между ПНЯ и аутоиммунными заболеваниями, представляется актуальным освещение вопросов взаимовлияния овариальной функции женщин с ПНЯ и ревматических заболеваний (в частности, системной красной волчанки, ревматоидного артрита и системной склеродермии), что представлено в обзоре. Заместительная гормональная терапия может быть рекомендована женщинам с ПНЯ для повышения качества их жизни.</p></trans-abstract><kwd-group xml:lang="en"><kwd>premature ovarian insufficiency</kwd><kwd>menopause</kwd><kwd>anti-ovarian antibodies</kwd><kwd>systemic lupus erythematosus</kwd><kwd>rheumatoid arthritis</kwd><kwd>systemic scleroderma</kwd><kwd>rheumatic diseases</kwd><kwd>hormone replacement therapy</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>преждевременная недостаточность яичников</kwd><kwd>менопауза</kwd><kwd>антиовариальные антитела</kwd><kwd>системная красная волчанка</kwd><kwd>ревматоидный артрит</kwd><kwd>системная склеродермия</kwd><kwd>ревматические заболевания</kwd><kwd>заместительная гормональная терапия</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The research and analysis were carried out within the fundamental research project of Nasonova Institute of Rheumatology "Development of a personalized program for the treatment of refractory rheumatoid arthritis based on the study of molecular genetic and molecular biological predictors. Development and testing of a register of patients with rheumatoid arthritis resistant to basic anti-inflammatory therapy"; №1021051503137-7.</funding-statement><funding-statement xml:lang="ru">Поисково-аналитическая работа выполнена в рамках фундаментальной научной тематики ФГБНУ НИИ Ревматологии им. В.А. Насоновой: «Разработка персонализированной программы лечения рефрактерного ревматоидного артрита на основе изучения молекулярно-генетических и молекулярно-биологических предикторов. Создание и апробация регистра пациентов с ревматоидным артритом, резистентных к базисной противовоспалительной терапии» №1021051503137-7».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI; Webber L, Davies M, Anderson R, et al. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-37. DOI:10.1093/humrep/dew027</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Адамян Л.В., Пивазян Л.Г., Антонова А.А. Преждевременная недостаточность яичников и аутоиммунитет: есть ли взаимосвязь? Проблемы репродукции. 2022;28(6):116-24 [Adamyan LV, Pivazyan LG, Antonova AA. Autoimmunity and premature ovarian insufficiency – up-to-date. Russian Journal of Human Reproduction. 2022;28(6):116-24 (in Russian)]. DOI:10.17116/repro202228061116</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Chon SJ, Umair Z, Yoon MS. Premature Ovarian Insufficiency: Past, Present, and Future. Front Cell Dev Biol. 2021;9:672890. DOI:10.3389/fcell.2021.672890</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Адамян Л.В., Андреева Е.Н., Артымук H.В., и др. Аменорея и олигоменорея. Клинические рекомендации. М.: Российское общество акушеров-гинекологов, 2021 [Adamian LV, Andreeva EN, Artymuk NV, et al. Amenoreia i oligomenoreia. Klinicheskiie rekomendatsii. Moscow: Rossiiskoie obshchestvo akusherov-ginekologov, 2021 (in Russian)].</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Кравченко Е.Н., Воронцова М.С. Преждевременная недостаточность яичников, современный взгляд на проблему. Мать и дитя в Кузбассе. 2022;88(1):4-10 [Kravchenko EN, Vorontsova MS. Premature ovarian insufficiency: modern view of the problem. Mat’ i ditia v Kuzbasse. 2022;88(1):4-10 (in Russian)]. DOI:10.24412/2686-7338-2022-1-4-10</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ishizuka B. Current Understanding of the Etiology, Symptomatology, and Treatment Options in Premature Ovarian Insufficiency (POI). Front Endocrinol (Lausanne). 2021;12:626924. DOI:10.3389/fendo.2021.626924.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Christin-Maitre S, Givony M, Albarel F, et al. Position statement on the diagnosis and management of premature/primary ovarian insufficiency (except Turner Syndrome). Ann Endocrinol (Paris). 2021;82(6):555-71. DOI:10.1016/j.ando.2021.09.001.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Адамян Л.В., Пивазян Л.Г. Междисциплинарный подход и современное состояние вопроса о преждевременном старении яичников (обзор литературы). Проблемы репродукции. 2023;29(1):94-103 [Adamyan LV, Pivazyan LG. Interdisciplinary approach and the current state of the issue of premature ovarian aging (literature review). Russian Journal of Human Reproduction. 2023;29(1):94-103 (in Russian)]. DOI:10.17116/repro20232901194</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Андреева Е.Н., Абсатарова Ю.С., Ахматова Р.Р., и др. Преждевременная недостаточность яичников: от основ патогенеза к перспективам в лечении. Вопросы гинекологии, акушерства и перинатологии. 2021;20(5):100-7 [Andreeva EN, Absatarova YS, Akhmatova RR, et al. Primary ovarian insufficiency: from basis of pathogenesis to treatment perspectives. Gynecology, Obstetrics and Perinatology. 2021;20(5):100-7 (in Russian)]. DOI:10.20953/1726-1678-2021-5-100-107</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Forges T, Monnier-Barbarino P, Faure GC, Béné MC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update. 2004;10(2):163-75. DOI:10.1093/humupd/dmh014</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Domniz N, Meirow D. Premature ovarian insufficiency and autoimmune diseases. Best Pract Res Clin Obstet Gynaecol. 2019;60:42-55. DOI:10.1016/j.bpobgyn.2019.07.008.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Euthymiopoulou K, Aletras AJ, Ravazoula P, et al. Antiovarian antibodies in primary Sjogren's syndrome. Rheumatol Int. 2007;27(12):1149-55. DOI:10.1007/s00296-007-0364-z</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Szeliga A, Calik-Ksepka A, Maciejewska-Jeske M, et al. Autoimmune Diseases in Patients with Premature Ovarian Insufficiency – Our Current State of Knowledge. Int J Mol Sci. 2021;22(5):2594. DOI:10.3390/ijms22052594</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Паневин Т.С., Молашенко Н.В., Трошина Е.А., Головенко Е.Н. Аутоиммунный полигландулярный синдром взрослых: современные представления о предикторах развития поражения миокарда и диагностике компонентов заболевания. Клиническая и экспериментальная тиреоидология. 2018;14(2):92-9 [Panevin TS, Molashenko NV, Troshina EA, Golovenko EN. Autoimmune polyglandular syndrome of adults: current ideas about predictors development of damage of a myocardium and diagnostics of components of a disease. Clinical and Experimental Thyroidology. 2018;14(2):92-9 (in Russian)]. DOI:10.14341/ket9641</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Zhen X, Qiao J, Li R, et al. Serologic autoimmunologic parameters in women with primary ovarian insufficiency. BMC Immunol. 2014;15:11. DOI:10.1186/1471-2172-15-11</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Mignot MH, Schoemaker J, Kleingeld M, et al. Premature ovarian failure. I: The association with autoimmunity. Eur J Obstet Gynecol Reprod Biol. 1989;30(1):59-66. DOI:10.1016/0028-2243(89)90094-4</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Власова Г.А., Перминова С.Г., Кошелева Н.М., Веюкова М.А. Влияние терапии иммуновоспалительных ревматических заболеваний на репродуктивную функцию. Акушерство и гинекология. 2021;7:53-60 [Vlasova GA, Perminova SG, Kosheleva NM, Veyukova MA. Impact of therapy for autoimmune rheumatic diseases on reproductive function. Obstetrics and Gynecology. 2021;7:53-60 (in Russian)]. DOI:10.18565/aig.2021.7.53-60</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Перминова С.Г., Власова Г.А., Кошелева Н.М. Репродуктивная функция у женщин с ревматоидным артритом: влияние заболевания и терапии метотрексатом на уровень антимюллерова гормона. Акушерство и гинекология. 2020;4:104-10 [Perminova SG, Vlasova GA, Kosheleva NM. Reproductive function of women with rheumatoid arthritis: the effect of the disease and methotrexate therapy on the serum level of anti-Müllerian hormone. Obstetrics and Gynecology. 2020;4:104-10 (in Russian)]. DOI:10.18565/aig.2020.4.104-110</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Алекберова З.С., Егорова О.Н., Голоева Р.Г., Черкасова М.В. Антиммюллеров гормон при системной красной волчанке. Современная ревматология. 2021;15(1):105-10 [Alekberova ZS, Egorova ON, Goloeva RG, et al. Anti-Mullerian hormone in systemic lupus erythematosus. Modern Rheumatology Journal. 2021;15(1):105-10 (in Russian)]. DOI:10.14412/1996-7012-2021-1-105-110</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Grossmann B, Saur S, Rall K, et al. Prevalence of autoimmune disease in women with premature ovarian failure. Eur J Contracept Reprod Health Care. 2020;25(1):72-5. DOI:10.1080/13625187.2019.1702638</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Pasoto SG, Viana VS, Mendonca BB, et al. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus? J Rheumatol. 1999;26(5):1087-93.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Karakus S, Sahin A, Durmaz Y, et al. Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study. J Obstet Gynaecol Res. 2017;43(2):303-7. DOI:10.1111/jog.13216</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Henes M, Froeschlin J, Taran FA, et al. Ovarian reserve alterations in premenopausal women with chronic inflammatory rheumatic diseases: impact of rheumatoid arthritis, Behçet's disease and spondyloarthritis on anti-Müllerian hormone levels. Rheumatology (Oxford). 2015;54(9):1709-12. DOI:10.1093/rheumatology/kev124</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Brouwer J, Dolhain RJ, Hazes JM, et al. Reduced Ovarian Function in Female Rheumatoid Arthritis Patients Trying to Conceive. ACR Open Rheumatol. 2019;1(5):327-35. DOI:10.1002/acr2.11043</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. J Rheumatol. 2019;46(5):455-9. DOI:10.3899/jrheum.180176</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Giambalvo S, Garaffoni C, Silvagni E, et al. Factors associated with fertility abnormalities in women with systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev. 2022;21(4):103038. DOI:10.1016/j.autrev.2022.103038</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME. The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev. 2010;9(5):A277-87. DOI:10.1016/j.autrev.2009.12.008</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mok CC, Lau CS, Wong RW. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30(6):426-35. DOI:10.1053/sarh.2001.22498</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Fernández M, Calvo-Alén J, Alarcón GS, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXI. Disease activity, damage accrual, and vascular events in pre- and postmenopausal women. Arthritis Rheum. 2005;52(6):1655-64. DOI:10.1002/art.21048</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Boddaert J, Huong DLT, Amoura Z, el al. Late-onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore). 2004;83(6):348-59. DOI:10.1097/01.md.0000147737.57861.7c</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Tomic-Lucic A, Petrovic R, Radak-Perovic M, et al. Late-onset systemic lupus erythematosus: clinical features, course, and prognosis. Clin Rheumatol. 2013;32(7):1053-8. DOI:10.1007/s10067-013-2238-y</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Talsania M, Scofield RH. Menopause and Rheumatic Disease. Rheum Dis Clin North Am. 2017;43(2):287-302. DOI:10.1016/j.rdc.2016.12.011</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Sanches-Guerrero J, Romero-Diaz J, Mendoza-Fuentes A, et al. Menopause in systemic lupus erythematosus. Age at menopause and clinical characteristics. Arthritis Rheum. 1999;42 Suppl. 9:205.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Mok CC, Lau CS, Ho CT, et al. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998;27(5):342-6. DOI:10.1080/0300974985015435</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>González LA, Pons-Estel GJ, Zhang JS, et al. Effect of age, menopause and cyclophosphamide use on damage accrual in systemic lupus erythematosus patients from LUMINA, a multiethnic US cohort (LUMINA LXIII). Lupus. 2009;18(2):184-6. DOI:10.1177/0961203308098988</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Mayorga J, Alpízar-Rodríguez D, Prieto-Padilla J, et al. Prevalence of premature ovarian failure in patients with systemic lupus erythematosus. Lupus. 2016;25(7):675-83. DOI:10.1177/0961203315622824</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Di Mario C, Petricca L, Gigante MR, et al. Anti-Müllerian hormone serum levels in systemic lupus erythematosus patients: Influence of the disease severity and therapy on the ovarian reserve. Endocrine. 2019;63(2):369-75. DOI:10.1007/s12020-018-1783-1</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Alpízar-Rodríguez D, Romero-Díaz J, Sánchez-Guerrero J, et al. Age at natural menopause among patients with systemic lupus erythematosus. Rheumatology (Oxford). 2014;53(11):2023-9. DOI:10.1093/rheumatology/keu222</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Lawrenz B, Henes J, Henes M, et al. Impact of systemic lupus erythematosus on ovarian reserve in premenopausal women: evaluation by using anti-Muellerian hormone. Lupus. 2011;20(11):1193-7. DOI:10.1177/0961203311409272</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Morel N, Bachelot A, Chakhtoura Z, et al. Study of anti-Müllerian hormone and its relation to the subsequent probability of pregnancy in 112 patients with systemic lupus erythematosus, exposed or not to cyclophosphamide. J Clin Endocrinol Metab. 2013;98(9):3785-92. DOI:10.1210/jc.2013-1235</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-7. DOI:10.3109/09513590.2011.650752</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41(5):831-7. DOI:10.1002/1529-0131(199805)41:5&lt;831::AID-ART9&gt;3.0.CO;2-1</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Safiri S, Kolahi AA, Hoy D, et al. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(11):1463-71. DOI:10.1136/annrheumdis-2019-215920</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Prasad P, Verma S, Surbhi, et al. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem. 2023;478(1):69-88. DOI:10.1007/s11010-022-04492-3</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Насонов Е.Л., Лила А.М., Каратеев Д.Е., и др. Ревматоидный артрит. Клинические рекомендации. М.: Ассоциация ревматологов России, Российская ревматологическая ассоциация «Надежда», 2021 [Nasonov EL, Lila AM, Karateyev DE, et al. Revmatoidnyi artrit. Klinicheskiie rekomendatsii. Moscow: Assotsiatsiia revmatologov Rossii, Rossiyskaia revmatologicheskaia assotsiatsiia “Nadezhda”, 2021 (in Russian)].</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Brouwer J, Laven JS, Hazes JM, et al. Levels of serum anti-Müllerian hormone, a marker for ovarian reserve, in women with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013;65(9):1534-8. DOI:10.1002/acr.22013</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Del Junco DJ, Annegers JF, Coulam CB, Luthra HS. The relationship between rheumatoid arthritis and reproductive function. Br J Rheumatol. 1989;28 Suppl. 1:33-45. DOI:10.1093/rheumatology/xxviii.suppl_1.33</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Banas T, Hajdyla-Banas I, Pitynski K, et al. Age at natural menopause in women on long-term methotrexate therapy for rheumatoid arthritis. Menopause. 2016;23(10):1130-8. DOI:10.1097/GME.0000000000000674</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Pikwer M, Nilsson JÅ, Bergström U, et al. Early menopause and severity of rheumatoid arthritis in women older than 45 years. Arthritis Res Ther. 2012;14(4):R190. DOI:10.1186/ar4021</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Merlino LA, Cerhan JR, Criswell LA, et al. Estrogen and other female reproductive risk factors are not strongly associated with the development of rheumatoid arthritis in elderly women. Semin Arthritis Rheum. 2003;33(2):72-82. DOI:10.1016/s0049-0172(03)00084-2</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Wong LE, Huang WT, Pope JE, et al. Effect of age at menopause on disease presentation in early rheumatoid arthritis: results from the Canadian Early Arthritis Cohort. Arthritis Care Res (Hoboken). 2015;67(5):616-23. DOI:10.1002/acr.22494</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Pfeifer EC, Crowson CS, Amin S, et al. The influence of early menopause on cardiovascular risk in women with rheumatoid arthritis. J Rheumatol. 2014;41(7):1270-5. DOI:10.3899/jrheum.131234</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Pikwer M, Bergström U, Nilsson JÅ, et al. Early menopause is an independent predictor of rheumatoid arthritis. Ann Rheum Dis. 2012;71(3):378-81. DOI:10.1136/ard.2011.200059</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Beydoun HA, el-Amin R, McNeal M, et al. Reproductive history and postmenopausal rheumatoid arthritis among women 60 years or older: Third National Health and Nutrition Examination Survey. Menopause. 2013;20(9):930-5. DOI:10.1097/GME.0b013e3182a14372</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):924-39. DOI:10.1002/acr.24596</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492-509. DOI:10.1136/annrheumdis-2013-204573</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol. 1996;14(5):1718-29. DOI:10.1200/JCO.1996.14.5.1718</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Eudy AM, McDaniel G, Hurd WW, Clowse ME. Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis. J Rheumatol. 2019;46(5):455-9. DOI:10.3899/jrheum.180176</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Ананьева Л.П. Новые направления в лечении системной склеродермии (системного прогрессирующего склероза). Доктор. Ру. 2021;20(7):32-9 [Ananieva LP. New Approaches in Management of Generalized Scleroderma (Progressive Systemic Sclerosis). Doctor.Ru. 2021; 20(7):32-9 (in Russian)]. DOI:10.31550/1727-2378-2021-20-7-32-39</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Ананьева Л.П. Лечение системной склеродермии с учетом национальных рекомендаций и рекомендаций Eвропейской лиги по борьбе с ревматизмом (EULAR). Фарматека. 2014;21(10):79-86 [Anan'ieva LP. Lecheniie sistemnoi sklerodermii s uchetom natsional'nykh rekomendatsii i rekomendatsii Evropeiskoi ligi po bor'be s revmatizmom (EULAR). Farmateka. 2014;21(10):79-86 (in Russian)].</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Hughes M, Pauling J, Armstrong-James L, et al. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19:102494. DOI:10.1016/j.autrev.2020.102494</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: A comprehensive systematic review and meta-analysis. Rheumatology. 2021;60:3121-33. DOI:10.1093/rheumatology/keab190</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Kowalska-Kępczyńska A. Systemic Scleroderma-Definition, Clinical Picture and Laboratory Diagnostics. J Clin Med. 2022;11(9):2299. DOI:10.3390/jcm11092299</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Sampaio-Barros PD, Samara AM, Marques Neto JF. Gynaecologic history in systemic sclerosis. Clin Rheumatol. 2000;19(3):184-7. DOI:10.1007/s100670050152</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Адамян Л.В., Андреева Е.Н., Аполихина И.А., и др. Менопауза и климактерическое состояние у женщины. Клинические рекомендации. М.: Российское общество акушеров-гинекологов, 2021 [Adamian LV, Andreeva EN, Apolikhina IA, et al. Menopauza i klimaktericheskoie sostoianiie u zhenshchiny. Klinicheskiie rekomendatsii. Moscow: Rossiiskoie obshchestvo akusherov-ginekologov, 2021 (in Russian)].</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>La Montagna G, Vatti M, Valentini G, Tirri G. Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause. Clin Rheumatol. 1991;10(1):18-22. DOI:10.1007/BF02208027</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Bhadauria S, Moser DK, Clements PJ, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol. 1995;172(2 Pt. 1):580-7. DOI:10.1016/0002-9378(95)90576-6</mixed-citation></ref></ref-list></back></article>
